Arndt Justus Georg Schottelius
Director/Board Member bei GUBRA A/S
Vermögen: 253 515 $ am 31.03.2024
Aktive Positionen von Arndt Justus Georg Schottelius
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GUBRA A/S | Director/Board Member | 01.01.2022 | - |
Independent Dir/Board Member | 01.01.2022 | - | |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | Chief Executive Officer | 01.03.2024 | - |
Karriereverlauf von Arndt Justus Georg Schottelius
Ehemalige bekannte Positionen von Arndt Justus Georg Schottelius
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AFFIMED N.V. | Chief Tech/Sci/R&D Officer | 01.04.2020 | 29.02.2024 |
MORPHOSYS AG | Corporate Officer/Principal | - | 01.03.2017 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | 01.05.2017 | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | - | - |
Ausbildung von Arndt Justus Georg Schottelius
University of Freiburg | Doctorate Degree |
Statistik
International
Deutschland | 4 |
Vereinigtes Königreich | 3 |
Vereinigte Staaten | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
AFFIMED N.V. | Health Technology |
MORPHOSYS AG | Health Technology |
GUBRA A/S | Commercial Services |
Private Unternehmen | 3 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | Health Technology |